ArticleCancer medicine2026
Body Weight Status and Its Association With Patient-Reported Outcomes in Women With Non-Metastatic ER-Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine associations of body mass index (BMI) with sociodemographic, clinical, treatment-related, psychosocial, and patient-reported outcomes among women with non-metastatic estrogen receptor-positive (ER+) breast cancer receiving adjuvant endocrine therapy.
methodsThis multicenter cross-sectional study included 557 women treated at 11 Brazilian public and private institutions from June 2021 to March 2024. Participants were classified as having normal weight, overweight, or obesity. Health-related quality of life was assessed using the EORTC QLQ-C30 and QLQ-BR23. Characteristics were compared across BMI categories using chi-square or Fisher's exact test and Kruskal-Wallis test. Multinomial logistic regression examined factors associated with BMI category, using normal weight as the reference.
resultsOf 557 participants, 172 had normal weight, 234 were overweight, and 151 had obesity. Education, comorbidities, hospital type, cancer stage, endocrine therapy, axillary dissection, prior chemotherapy, and radiotherapy differed across BMI categories. Participants with obesity had poorer physical functioning and greater pain. In the final model (n = 554), axillary dissection (OR = 2.51; 95% CI = 1.37-4.59) and continuous medication use (OR = 2.92; 95% CI = 1.78-4.79) were associated with obesity versus normal weight. Tamoxifen was inversely associated with overweight (OR = 0.58; 95% CI = 0.36-0.91), whereas low treatment adherence (OR = 1.54; 95% CI = 1.01-2.35) and continuous medication use (OR = 1.68; 95% CI = 1.10-2.58) were positively associated.
conclusionOverweight and obesity were common and associated with sociodemographic, clinical, treatment-related, and selected quality-of-life characteristics. These findings support integrated survivorship care addressing weight-related health, comorbidities, functional limitations, and symptom burden. Longitudinal studies are needed to clarify temporal relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.